SENSEX 77414.92 ▼ (0.25%)
BSE BANKEX 59542.38 ▲ (0.36%)

INDOCO REMEDIES

BSE: 532612 29 Sep 2025
Healthcare
₹ 294.2
Indoco Remedies Ltd. specializes in Pharmaceuticals within the Healthcare sector.

INDOCO REMEDIES - Share Price & Details

Market Cap
₹2,589
High /Low
388.0 / 190.0
Stock P/E
NA
Book Value
₹120.0
Dividend Yield
0.53
ROCE
2.76
ROE
₹-0.86
Face Value
2.0
PEG Ratio
NA
EVEBITDA
₹22.7
Debt
754
CMP / FCF
-44.6
Debt to equity
₹0.68
NP Ann
-8.73
High price all time
530.0
Piotroski score
₹2.0
Graham Number
NA
No. Eq. Shares
9.22
Net CF
₹-0.41
Net profit
-8.73
Price to book value
2.35
Interest Coverage
₹0.85
Low price all time
13.9
Industry PE
33.8
Reserves
₹1,085
Free Cash Flow
₹-164

Broker Recommendations

Date Author Type Reco Price Target Price Potential Source PDF Link
25 Jul 2025 Prabhudas Lilladher Hold ₹321.95 ₹325 2.4% moneycontrol View
22 Jan 2025 Prabhudas Lilladher Hold ₹342.35 ₹325 13.1% moneycontrol View
24 Oct 2024 Prabhudas Lilladher Buy ₹315.05 ₹320 -1.2% moneycontrol View
25 Jul 2024 Prabhudas Lilladher Buy ₹324.1 ₹320 -0.1% moneycontrol View
24 Jan 2024 Prabhudas Lilladher Buy ₹371.35 ₹380 18.6% moneycontrol View

Price Chart


Volume Chart


Peer Comparison

Stock Total Income Net Profit Net Sales EPS Market Cap (in Cr) P/E
FABINO ENTERPRISES LIMITEDNANANANA5.0984.8
Triochem Products Ltd.,NANANANA0
INDOCO REMEDIES LTD.3981.1-280.63925.3-3.042,589
Krsnaa Diagnostics Limited1796.13195.621756.156257432.1
DR.AGARWALS EYE HOSPITAL LTD.NANANANA225939.1

Peer Comparison Chart


About INDOCO REMEDIES

Indoco Remedies Ltd., with Security Code 532612, is a leading player in the Pharmaceuticals industry, categorized under the Healthcare sector, offering Equity instruments.


Order Book


Latest News

Here's Why Shareholders Should Examine Indoco Remedies Limited's (NSE:INDOCO) CEO Compensation Package More Closely

(08 Sep 2025)
Key Insights Indoco Remedies will host its Annual General Meeting on 11th of September Total pay for CEO Sundeep...
Read more →

Indoco Remedies gets USFDA nod for venous thromboembolism drug Rivaroxaban

(18 Aug 2025)
Mumbai: Indoco Remedies Ltd. has received final approval from the US Food and Drug Administration (USFDA) for the Company's Abbreviated New...
Read more →

Indoco Remedies receives final USFDA approval for rivaroxaban tablets

(18 Aug 2025)
Indoco Remedies Ltd. has received final approval from the USFDA for its Abbreviated New Drug Application (ANDA) for Rivaroxaban Tablets USP,...
Read more →

Indoco Remedies receives USFDA approval for Rivaroxaban Tablets

(16 Aug 2025)
Indoco Remedies announced final approval of the Company's Abbreviated New Drug Application (ANDA) for Rivaroxaban Tablets USP, 2.5 mg,...
Read more →

Indoco Remedies clocks Rs 35.6 crore loss in Q1 vs Rs 2.6 crore profit last year

(16 Aug 2025)
Mumbai, July 24 (IANS) Pharmaceutical company Indoco Remedies Limited on Thursday reported a net loss of Rs 35.6 crore in the June quarter...
Read more →

Is Indoco Remedies Limited (532612) a Good Long Term Bet - Achieve superior capital gains with smart trades

(06 Aug 2025)
Is Indoco Remedies Limited (532612) a Good Long Term Bet ✌️【Investor Updates】✌️ Grow smarter with free access to high-growth picks and...
Read more →